organization · Reporting owner

HHLR ADVISORS, LTD.

Disclosed activity across 3 companies

Tapewire entity: 67918
SEC CIK: 0001762304

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cellular Biomedicine Group, Inc.CBMG · Entity 142413	10% owner	November 10, 2019	November 20, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cellular Biomedicine Group, Inc.

Report date November 10, 2019 · Filed November 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	235,214	Reported balance Holding disclosure · report date 2019-11-10 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 235,214 F1: The securities to which this filing relates are held directly by Gaoling Fund, L.P. ("Gaoling") and YHG Investment, L.P. ("YHG," together with Gaoling, the "Hillhouse Entities"). Hillhouse Capital Advisors, Ltd. ("HCA" or, the "Reporting Person") acts as the sole management company of Gaoling and sole general partner of YHG. HCA is hereby deemed to be the sole beneficial owner of, and to solely control the voting and investment power of, the shares of Common Stock held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities to which this filing relates are held directly by Gaoling Fund, L.P. ("Gaoling") and YHG Investment, L.P. ("YHG," together with Gaoling, the "Hillhouse Entities"). Hillhouse Capital Advisors, Ltd. ("HCA" or, the "Reporting Person") acts as the sole management company of Gaoling and sole general partner of YHG. HCA is hereby deemed to be the sole beneficial owner of, and to solely control the voting and investment power of, the shares of Common Stock held by the Hillhouse Entities. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ArriVent BioPharma, Inc.

Report date December 10, 2025 · Filed February 03, 2026

Jointly reported with HILLHOUSE INVESTMENT MANAGEMENT, LTD.

Section 16 reporting ended · disclosed 2026-02-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	3,929,117	Reported balance After 2025-12-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-10 · Sale · Disposed 555,555 · Balance 3,929,117 F1: The securities reported herein were held by HACF, L.P., an exempted Cayman Islands limited partnership ("HACF"). HHLR (as defined below) acts as the sole management company of HACF. F2: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Venture Fund V"), VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). HIM (as defined below) acts as the sole management company of each of Venture Fund V, Healthcare Fund and Venture Fund VI. F3: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F4: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein were held by HACF, L.P., an exempted Cayman Islands limited partnership ("HACF"). HHLR (as defined below) acts as the sole management company of HACF.

F2: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Venture Fund V"), VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). HIM (as defined below) acts as the sole management company of each of Venture Fund V, Healthcare Fund and Venture Fund VI.

F3: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly.

F4: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

BeOne Medicines Ltd.

Report date December 02, 2024 · Filed December 04, 2024

Jointly reported with HILLHOUSE INVESTMENT MANAGEMENT, LTD.

Section 16 reporting ended · disclosed 2024-12-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnotes	125,045,741	Reported balance After 2024-12-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-12-02 · Sale · Disposed 17,842,500 · Balance 125,045,741 F1: The ordinary shares, par value $0.0001 per share ("Ordinary Shares") sold were in the form of American Depositary Shares ("ADSs"). The reported price is the price of each ADS sold; the price was paid in USD. Each ADS represents 13 Ordinary Shares. F2: Consists of (i) 111,597,423 Ordinary Shares held by funds managed by HHLR (as defined below), of which 36,011,300 Ordinary Shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 Ordinary Shares held by a fund managed by HIM (as defined below), of which 13,445,978 Ordinary Shares are held in the form of 1,034,306 ADSs. F3: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"), and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F4: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The ordinary shares, par value $0.0001 per share ("Ordinary Shares") sold were in the form of American Depositary Shares ("ADSs"). The reported price is the price of each ADS sold; the price was paid in USD. Each ADS represents 13 Ordinary Shares.

F2: Consists of (i) 111,597,423 Ordinary Shares held by funds managed by HHLR (as defined below), of which 36,011,300 Ordinary Shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 Ordinary Shares held by a fund managed by HIM (as defined below), of which 13,445,978 Ordinary Shares are held in the form of 1,034,306 ADSs.

F3: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"), and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly.

F4: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 10, 2025 Filed Feb 3, 2026 21:05 UTC	ArriVent BioPharma, Inc. AVBP · Entity 4699	SaleCommon Stock	555,555	$23.37	$12,983,320.35	Disclosure SEC source: 0000902664-26-000675 · ownership.xml · nonDerivative · entry 1 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,929,117 F1 · shares: The securities reported herein were held by HACF, L.P., an exempted Cayman Islands limited partnership ("HACF"). HHLR (as defined below) acts as the sole management company of HACF. F2 · balance_after: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Venture Fund V"), VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). HIM (as defined below) acts as the sole management company of each of Venture Fund V, Healthcare Fund and Venture Fund VI. F3 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document
December 02, 2024 Filed Dec 4, 2024 21:06 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	17,842,500	$200.00	$3,568,500,000.00	Disclosure SEC source: 0000902664-24-006828 · ownership.xml · nonDerivative · entry 1 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 125,045,741 F1 · price: The ordinary shares, par value $0.0001 per share ("Ordinary Shares") sold were in the form of American Depositary Shares ("ADSs"). The reported price is the price of each ADS sold; the price was paid in USD. Each ADS represents 13 Ordinary Shares. F2 · balance_after: Consists of (i) 111,597,423 Ordinary Shares held by funds managed by HHLR (as defined below), of which 36,011,300 Ordinary Shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 Ordinary Shares held by a fund managed by HIM (as defined below), of which 13,445,978 Ordinary Shares are held in the form of 1,034,306 ADSs. F3 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"), and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F4 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document
January 30, 2024 Filed Feb 1, 2024 21:47 UTC	ArriVent BioPharma, Inc. AVBP · Entity 4699	ConversionSeries B Preferred Stock · Derivative	4,761,903	$0.00	$0.00	Disclosure SEC source: 0000902664-24-000903 · ownership.xml · derivative · entry 5 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 313,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F3 · shares: The securities reported herein are held by VSUM VIII and ARVT Holdings Limited ("ARVT"). VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Hillhouse Venture VI"). HIM acts as the sole management company of each of Hillhouse Healthcare and Hillhouse Venture VI. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document
January 30, 2024 Filed Feb 1, 2024 21:47 UTC	ArriVent BioPharma, Inc. AVBP · Entity 4699	ConversionSeries A Preferred Stock · Derivative	55,000,000	$0.00	$0.00	Disclosure SEC source: 0000902664-24-000903 · ownership.xml · derivative · entry 4 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,616,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F2 · shares: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI") and VSUM VIII Holdings Limited ("VSUM VIII"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Hillhouse Venture V") and VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Hillhouse Healthcare"). HIM (as defined below) acts as the sole management company of each of Hillhouse Venture V and Hillhouse Healthcare. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document
January 30, 2024 Filed Feb 1, 2024 21:47 UTC	ArriVent BioPharma, Inc. AVBP · Entity 4699	PurchaseCommon Stock	555,555	$18.00	$9,999,990.00	Disclosure SEC source: 0000902664-24-000903 · ownership.xml · nonDerivative · entry 3 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 4,484,672 F4 · shares: The securities reported herein are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"). HHLR (as defined below) acts as the sole management company of HHLR Fund. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document
January 30, 2024 Filed Feb 1, 2024 21:47 UTC	ArriVent BioPharma, Inc. AVBP · Entity 4699	ConversionCommon Stock	313,076	Not disclosed	Not disclosed	Disclosure SEC source: 0000902664-24-000903 · ownership.xml · nonDerivative · entry 2 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,929,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI") and VSUM VIII Holdings Limited ("VSUM VIII"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Hillhouse Venture V") and VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Hillhouse Healthcare"). HIM (as defined below) acts as the sole management company of each of Hillhouse Venture V and Hillhouse Healthcare. F3 · shares: The securities reported herein are held by VSUM VIII and ARVT Holdings Limited ("ARVT"). VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Hillhouse Venture VI"). HIM acts as the sole management company of each of Hillhouse Healthcare and Hillhouse Venture VI. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document
January 30, 2024 Filed Feb 1, 2024 21:47 UTC	ArriVent BioPharma, Inc. AVBP · Entity 4699	ConversionCommon Stock	3,616,041	Not disclosed	Not disclosed	Disclosure SEC source: 0000902664-24-000903 · ownership.xml · nonDerivative · entry 1 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,616,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI") and VSUM VIII Holdings Limited ("VSUM VIII"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Hillhouse Venture V") and VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Hillhouse Healthcare"). HIM (as defined below) acts as the sole management company of each of Hillhouse Venture V and Hillhouse Healthcare. F3 · shares: The securities reported herein are held by VSUM VIII and ARVT Holdings Limited ("ARVT"). VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Hillhouse Venture VI"). HIM acts as the sole management company of each of Hillhouse Healthcare and Hillhouse Venture VI. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis. F5 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F6 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document
June 14, 2023 Filed Jun 15, 2023 23:25 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	273,728	$207.72	$56,857,986.35	Disclosure SEC source: 0000902664-23-003603 · ownership.xml · nonDerivative · entry 3 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 142,888,241 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F4 · balance_after: Consists of (i) 129,439,923 ordinary shares held by funds managed by HHLR (as defined below), of which 53,853,800 ordinary shares are held in the form of 4,142,600 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM (as defined below), of which 13,445,978 ordinary shares are held in the form of 1,034,306 ADSs. F5 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F6 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document
June 13, 2023 Filed Jun 15, 2023 23:25 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	313,400	$128.43	$40,251,058.90	Disclosure SEC source: 0000902664-23-003603 · ownership.xml · nonDerivative · entry 2 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 143,161,969 F2 · price: The ordinary shares were sold through the Stock Exchange of Hong Kong, the price was paid in HKD. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from HKD127.75 to HKD128.5985, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ordinary shares sold at each separate price. F5 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F6 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document
June 13, 2023 Filed Jun 15, 2023 23:25 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	611,000	$211.45	$129,197,294.20	Disclosure SEC source: 0000902664-23-003603 · ownership.xml · nonDerivative · entry 1 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 143,475,369 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F5 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F6 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document
June 12, 2023 Filed Jun 13, 2023 01:57 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	968,812	$213.91	$207,240,996.95	Disclosure SEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 5 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 144,086,369 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F5 · balance_after: Consists of (i) 130,638,051 ordinary shares held by funds managed by HHLR (as defined below), of which 54,737,800 ordinary shares are held in the form of 4,210,600 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM (as defined below), of which 13,445,978 ordinary shares are held in the form of 1,034,306 ADSs. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document
June 12, 2023 Filed Jun 13, 2023 01:57 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	281,400	$130.83	$36,816,181.08	Disclosure SEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 4 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 145,055,181 F2 · price: The ordinary shares were sold through the Stock Exchange of Hong Kong, the price was paid in HKD. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from HKD131.7943 to HKD131.0298 inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ordinary shares sold at each separate price. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document
June 09, 2023 Filed Jun 13, 2023 01:57 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	328,952	$217.02	$71,388,603.82	Disclosure SEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 3 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 145,336,581 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document
June 09, 2023 Filed Jun 13, 2023 01:57 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	213,700	$130.35	$27,856,286.51	Disclosure SEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 2 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 145,665,533 F2 · price: The ordinary shares were sold through the Stock Exchange of Hong Kong, the price was paid in HKD. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from HKD130.2787 to HKD130.550, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ordinary shares sold at each separate price. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:57 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	SaleOrdinary Shares	1,163,825	$218.14	$253,881,789.95	Disclosure SEC source: 0000902664-23-003537 · ownership.xml · nonDerivative · entry 1 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 145,879,233 F1 · price: The shares sold were in the form of ADS. The reported price is the price of each ADS sold, the price was paid in USD. Each ADS represents 13 Ordinary Shares. F6 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F7 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document
August 22, 2022 Filed Aug 24, 2022 20:15 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	OtherOrdinary Shares	7,800	$0.00	$0.00	Disclosure SEC source: 0000902664-22-004100 · ownership.xml · nonDerivative · entry 1 HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 147,043,058 F1 · kind: Represents a transfer of shares by Qingqing Yi ("Mr. Yi"), a director of the Issuer and an employee of the Reporting Persons (as defined below), to certain funds managed by the Reporting Persons and for whose benefit he was holding the shares. The Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. F2 · balance_after: Consists of (i) 133,594,740 ordinary shares held by funds managed by HHLR (as defined below), of which 127,971,155 ordinary shares are held in the form of 9,843,935 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM (as defined below), of which 13,447,603 ordinary shares are held in the form of 1,034,431 ADSs. F3 · ownership.nature: This form is filed by (i) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR") and (ii) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, HHLR and HIM are filing this Form 4 jointly. F4 · ownership.nature: The securities to which this filing relates are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"), YHG Investment, L.P., an exempted Cayman Islands limited partnership ("YHG"), and BGN Holdings Limited, an exempted Cayman Islands company ("BGN"). HHLR acts as the sole management company of HHLR Fund and the sole investment manager of YHG. HIM acts as the sole management company of Hillhouse Fund II, L.P. ("Fund II"). BGN is wholly owned by Fund II. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.